Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics

26 Mar 2024
www.biospace.com
Gene Therapy
SAN DIEGO--(BUSINESS WIRE)-- Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovative research and development partnership with Volastra Therapeutics, a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability (CIN). The collaboration brings together Function’s CRISPR-enabled personalized functional genomics technology with Volastra’s expertise in CIN to expand patient selection for Volastra’s KIF18A inhibitorsKIF18A inhibitors across an array of solid tumors indications. Function is leveraging its CRISPR-enabled platform to understand disease in unprecedented and patient-specific detail. By moving beyond traditional gene sequencing to measuring gene function, the Volastra and Function teams aim to identify which patients would benefit from treatment with Volastra’s KIF18A inhibitorsKIF18A inhibitors. This technology has the potential to accelerate clinical development through predictive biomarkers, as well as novel target identification and validation, and ultimately lead to better patient and trial outcomes. “This collaboration serves as validation of our CRISPR-based approach to deciphering patient-specific drug target vulnerabilities in solid tumors. We are excited to partner with the world-class team at Volastra to accelerate the development of promising medicines that will impact the lives of patients and their families,” said Srinath Sampath, M.D., Ph.D., M.Phil., Co-founder and Chief Executive Officer of Function Oncology. Added Scott Drutman, M.D., Ph.D., Chief Medical Officer and Head of Research and Development at Volastra, “KIF18A inhibition holds tremendous promise for treating chromosomally unstable tumors. CRISPR technology has transformed precision medicine, and we are excited by the potential of Function’s innovative platform to expand the pool of patients that will benefit from KIF18A inhibitorsKIF18A inhibitors.” About Function Oncology Function is a San Diego-based precision medicine company advancing CRISPR-powered personalized functional genomics to understand serious diseases in unprecedented and patient-specific detail. The company was founded in 2019 and is funded by Andreessen Horowitz, Section 32, Casdin Capital, and ARE. Function’s platform moves beyond measuring gene sequence to instead measure gene function directly in clinical samples using CRISPR. This provides unique insight into patients and diseases, enabling identification of optimal treatment strategies for current patients, as well as driving development of an exciting internal pipeline of novel therapeutics. To learn more, please visit and follow us on LinkedIn. View source version on businesswire.com: Contacts Function Oncology Media Contact Katie Engleman, 1AB katie@1abmedia.com Source: Function Oncology View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.